MMF 500 - Tablet Mycophenolate Mofetil - 500mg 10 Tablet(s) / Strip Beacon Pharmaceuticals PLC Introduction: MMF 500 belongs to a group of medicines called immunosuppressants. It is used with other medicines to prevent your body from rejecting an organ (such as a kidney, heart or liver) after a transplant. It works by supressing your body’s immune system, so that it does not attack the new organ. The amount of MMF 500 you take and how often you take it depends on the type of transplant you have. Follow your doctor's instructions on this. You should take it on an empty stomach, at least 1 hour before or 2 hours after a meal. Swallow it as... Uses of MMF 500: Prevention of organ rejection in transplant patients Side effects of MMF 500: NauseaVomitingDiarrheaAbdominal painHeadacheHigh blood pressureDecreased white blood cell count (neutrophils) How to use MMF 500: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. MMF 500 may be taken with or without food, but it is better to take it at a fixed time. How MMF 500 works: MMF 500 is an immunosuppressant. It reduces the action of body's own defence system (the immune system) and prevents rejection of the transplanted organ. Indication: Prophylaxis of acute renal graft rejection, Prophylaxis of cardiac graft rejection, Liver Transplant Administration: Drug is taken on empty stomach 1 hour before or 2 hours after meals Once dosage is stabilized, MMF can be taken with food after kidney transplant Adult Dose: Oral Adult Prophylaxis of acute renal graft rejection As Mycophenolate Mofetil (MMF): 1 g twice daily starting w/in 72 hr of transplantation. Max: 2 g/day. Prophylaxis of cardiac graft rejection, Liver Transplant Adult: As Mycophenolate Mofetil (MMF):1.5 g bid starting within 5 days after transplantation. Child Dose: 3 months Prophylaxis of organ rejection in patients receiving allogeneic renal transplants As Mycophenolate Mofetil (MMF): MMF (suspension): 600 mg/m² PO q12hr; not to exceed 2 g/day MMF: BSA 1.25-1.5 m²: 750 mg capsule PO q12hr MMF: BSA >1.5 m²: 1 g capsule/tablet PO q12hr Renal Dose: Renal impairment MMF: In severe renal impairment (glomerular filtration rate [GFR] <25 mL/min/1.73 m²), not to exceed 1 g q12hr No dosage adjustment needed in renal transplant patients experiencing delayed graft function post-operatively. Contraindication: Pregnancy, lactation. Rare hereditary deficiency of hypoxanthine-guanine phosphoribosyltransferase (HGPRT), including Kelley-Seegmiller or Lesch-Nyhan syndrome. Mode of Action: Mycophenolic acid acts by blocking purine synthesis of human lymphocytes through reversible inhibition of inosine monophosphate dehydrogenase. It also inhibits proliferation of both T- and B- lymphocytes. Precaution: Teratogenic in animals; avoid inhalation or direct skin contact. Monitor patients for lymphoproliferative disorders; advise patient to limit exposure to sunlight/UV light. Perform CBCs; monitor for neutropenia. Mycophenolate mofetil and mycophenolate sodium are not interchangeable. Lactation: Unknown whether drug is excreted in breast milk; avoid using, or do not nurse Side Effect: >10% Hyperglycemia (44%),Hypercholesterolemia (41%),Hypomagnesemia (39%),Dyspnea (37%),Back pain (35%),Increased blood urea nitrogen (BUN) (35%),Leukopenia (34%),Pleural effusion (34%),Urinary tract infection (34%),Increasing frequency of cough (31%),Hypocalcemia (30%),Hypertension (28%),Abdominal pain (27%),Peripheral edema (27%),Anemia (26%),Fever (23%),Nausea (23%),Hyperkalemia (22%),Diarrhea (21%),Infection (21%),Headache (16%) 1-10% Melanoma (1.6-4.2%),Other malignancies (0.7-2.1%),Lymphoma (0.4-1%),Opportunistic infection (including herpes),Neutropenia,GI bleeding,Pulmonary fibrosis,Progressive multifocal leukoencephalopathy Potentially Fatal: Angioedema, anaphylaxis, fatal pulmonary fibrosis. Interaction: Increased plasma levels of both drugs when combined with aciclovir, valaciclovir, ganciclovir and valganciclovir. Reduced absorption with colestyramine, magnesium- and aluminium hydroxide-containing products, sevelamer and other calcium-free phosphate binders. Reduced plasma levels with ciclosporin, metronidazole, quinolones, rifamycins. May reduce plasma levels of progestins; may reduce efficacy of oral contraceptives. Increased plasma levels with probenecid. May reduce efficacy of live vaccines.